Clicky

Immutep Limited(IMM) News

Date Title
Jun 29 Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data
Jun 26 ASX Penny Stocks Spotlight: Arafura Rare Earths And Two More To Consider
Jun 24 With 51% institutional ownership, Immutep Limited (ASX:IMM) is a favorite amongst the big guns
Jun 23 High Growth Tech Stocks In Australia For June 2025
Jun 23 Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
Jun 19 Exploring Life360 And 2 Prominent High Growth Tech Stocks In Australia
May 27 Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
May 15 Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
Mar 10 Immutep Limited (IMMP): Among the Best Australian Stocks to Buy According to Billionaires
Feb 11 Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?
Jan 6 Patient Enrolment Completed for INSIGHT-003
Oct 10 Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
Jun 25 Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
Mar 24 11 Best ASX Stocks To Buy Now
Feb 5 10 Best Australian Stocks To Buy
Jan 4 First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
Dec 21 Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Dec 7 Immutep Receives A$2.6 million R&D Tax Incentive from French Government
Nov 27 Immutep (ASX:IMM) investors are sitting on a loss of 22% if they invested five years ago
Nov 9 Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma